Africa Map

African Press Agency

African Press Agency Logo

 Country Profile
 Useful Links
 Contact us

[Published: Friday September 25 2020]

 Volunteers to be injected with Covid-19 in challenge trials

LONDON, 25 Sept. - (ANA) - Volunteers will be deliberately infected with Covid-19 in “ground-breaking” trials aimed at speeding up vaccine development. 
Patients at the Royal Free Hospital in London will be inoculated with a vaccine developed by Imperial College, London, before being exposed to the coronavirus. 
So-called challenge trials are controversial, but can give a quick answers a vaccine’s effectiveness, says The Telegraph.
The potential vaccine, created by the University of Oxford and AstraZeneca, is “one of the front runners in the race for an effective immunisation against the coronavirus”, says The Telegraph.
It is “currently undergoing phase three clinical trials in around 30,000 people in the UK, the US, Brazil and South Africa, with the first results expected by October”.
Trump is reportedly looking at enacting a so-called “emergency use authorisation” through the US Food and Drug Administration to fast-track the vaccine for use in the US based on
results from the first 10,000 triallists.
Normally, “a vaccine would need to be studied in 30,000 people to pass the threshold for authorisation” in the US, reports the Financial Times.
AstraZeneca denied having discussed emergency use authorisation for the potential vaccine with the US government, saying it would be “premature to speculate on that possibility”.
Oxford University’s Jenner Institute had a head start thanks to previous work on a vaccine for a different type of coronavirus.  - (ANA) -
AB/ANA/25 September 2020 - - -

North South News website

Advertise banner

News icon Iran/Defence system
News icon Rohingya/Virtual fundraiser
News icon Burundi/Media repression
News icon China/Uighur camps
News icon WHO/Covid-19
News icon UN/75 years
News icon UN/Libya
News icon Conference/Rohingya
News icon Sudan/S. Sudan
News icon Oxford/Vaccine

AFRICAN PRESS AGENCY Copyright © 2005 - 2007